md:complex melanoceuticals

London, UK - September 20, 2014

The winning combination with Tranexamic acid, the definitive solution for hyperpigmentation:

Melasma is a common disorder of pigmentation, predominantly affecting women, characterised by the development of hyperpigmented tan, brown or grey patches, often symmetrically distributed in centrofacial, malar, mandibular and forehead areas. The exact pathogenesis of melasma is probably multifactorial; UV light exposure, genetic predisposition and hormonal influences are generally considered the major components.

Managing melasma is a difficult challenge that requires long-term treatment with a number of topical agents for which there are varying degrees of evidence of clinical efficacy. Hydroquinone has long been a mainstay for the topical treatment of hyperpigmentation; however, concerns regarding adverse effects such as ochronosis, allergic and irritant contact dermatitis, melanocyte toxicity and carcinogenicity, have prompted a search for alternative agents.

As there is no perfectly satisfactory agent for melasma, research is ongoing to develop newer, safer and more innovative treatment for this psychosocial disorder, which causes significant stress and embarrassment to the patient. Indeed, pigmentary disorders rank among the top 5 most common skin complaints in several ethnic groups, including blacks, Arabs, and South Asians.

In order to safely fight against the main factors causing the appearance of unsightly blemishes, md:ceuticals has developed md:complex melanoceuticals; this combines high concentrations of whitening, exfoliating, antioxidant and brightening active principles such as Tranexamic acid, Glutathione, Azelaic acid, Kojic acid, Arbutin, Glycolic acid, Ascorbic acid and Citric acid, which act in the different stages of the melanogenesis process, blocking the appearance of cutaneous hyperpigmentation while maintaining the integrity of the skin.

Whitening ingredients : activate the inhibiting mechanisms in different stages of the melanogenesis process: inhibit tyrosinase activity, stop dopaquinone formation; block the production of eumelanins (brown or black hyperpigmentation) by inhibiting dopatautomerase activity and suppress the transfer of melanosomes from melanocytes to epidermal keratinocytes, eliminating skin blemishes.

Exfoliating ingredients : accelerate epidermal renewal and enhance skin penetration of the active ingredients, lightening the skin tone, reducing imperfections and restoring a smoother texture.

Antioxidant and brightening ingredients : increase skin luminosity, softness and elasticity, promoting an even skin tone. Help prevent skin photo-aging, aiding in an accelerated recovery and renewal process.

md:complex melanoceuticals formulation includes Tranexamic acid (TA), whose efficacy has been proved by numerous clinical studies to reduce melasma severity without adverse reactions. TA inhibits melanin synthesis in epidermal melanocytes’ tyrosinase activity, blocking the interaction of melanocytes and keratinocytes by inhibition of the plasminogen/plasmin system, and also prevents ultraviolet ray induced pigmentation. The application of Tranexamic acid over 128 patients has shown a reduction in pigmentation of 95% in 20% of the patients, a reduction of 70% in 30% of the patients and a reduction of 60% in 33% of the patients.

Ascorbic acid enhances the Tranexamic acid absorption, enhancing the melanin reduction and optimizing results.

Tranexamic acid works as an excellent adjuvant in the treatment of melasma; it improves the efficacy of known effective treatments and reduces the chance of recurrence. All the pre-existing treatments of melasma aim at reducing the formation of melanin from melanocytes (depigmentation topical agents) and eliminating pre-existing melanin pigment (exfoliating actives). However, they may activate melanocytes by irritation, inflammation or by injuries to keratinocytes that lead to recurrence or post inflammatory hyperpigmentation. Tranexamic acid is now the only modality that can actually prevent the activation of melanocyte by sunlight, hormonal influence, and injured keratinocyte through the inhibition of the keratinocyte-activate-melanocyte pathway.

 

Press Contacts : md:ceuticals PR

md:ceuticals,the md:ceuticals logo, md:peel, md:complex, melanoceuticals and melan:off are trademarks of md:ceuticals. Other company and product names may be trademarks of their respective owners.